Literature DB >> 7447420

Interpretive standards for disk susceptibility tests with Sch 21420 and amikacin.

A L Barry, C Thornsberry, R N Jones, E H Gerlach.   

Abstract

Disk susceptibility tests with two structurally related aminoglycosides (amikacin and Sch 21420) were evaluated. Tests with 10- and 30-micrograms amikacin disks confirmed previous recommendations for interpretive zone standards; 30-micrograms disks are preferred. Tests with 10-, 20-, and 30-micrograms Sch 21420 disks led to similar conclusions. The 30-micrograms Sch 21420 disks are recommended, with zone standards of less than or equal to 14 mm for the resistant category (minimal inhibitory concentration, greater than or equal to 32 micrograms/ml) and greater than or equal to 17 mm for the susceptible category (minimal inhibitory concentration, less than or equal to 16 micrograms/ml). If a minimal inhibitory concentration breakpoint of less than or equal to 8 micrograms/ml is preferred for defining the susceptible category, somewhat different zone standards may be used (less than or equal to 15 mm and greater than or equal to 19mm). Further evaluation documented the fact that tests with 30-micrograms amikacin disks predicted resistance or susceptibility to Sch 21420 almost as well as did a 30-micrograms Sch 21420 disk. Thus, the class concept of disk testing was judged to applicable, and routine testing with Sch 21420 may not be required.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7447420      PMCID: PMC284059          DOI: 10.1128/AAC.18.4.616

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria.

Authors:  R C Moellering; C Wennersten; L J Kunz; J W Poitras
Journal:  Am J Med       Date:  1977-06       Impact factor: 4.965

2.  1-N HAPA gentamicin B, a new aminoglycoside active against gentamicin resistant isolates--activity compared to other aminoglycosides.

Authors:  H C Neu; K P Fu
Journal:  J Antibiot (Tokyo)       Date:  1978-05       Impact factor: 2.649

3.  Interpretation of the disk diffusion susceptibility test for amikacin: report of a collaborative study.

Authors:  J A Washington; P K Yu; T L Gavan; F D Schoenknecht; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

4.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

5.  The syntheses and biological properties of 1-N-(S-4-amino-2-hydroxybutyryl)-gentamicin B and 1-N-(S-3-amino-2-hydroxypropionyl)-gentamicin B.

Authors:  T L Nagabhushan; A B Cooper; H Tsai; P J Daniels; G H Miller
Journal:  J Antibiot (Tokyo)       Date:  1978-07       Impact factor: 2.649

6.  Biological activity of SCH 21420, the 1-N-S-alpha-hydroxy-beta-aminopropionyl derivative of gentamicin B.

Authors:  G H Miller; P J Chiu; J A Waitz
Journal:  J Antibiot (Tokyo)       Date:  1978-07       Impact factor: 2.649

7.  Serum concentrations and inhibitory ratios during amikacin therapy of gram-negative infections.

Authors:  L A Farchione; G M Chudzik
Journal:  J Clin Pharmacol       Date:  1978 Aug-Sep       Impact factor: 3.126

8.  Comparative in vitro activity of a semisynthetic derivative of gentamicin B (SCH 21420) and five other aminoglycosides.

Authors:  C Watanakunakorn
Journal:  J Antibiot (Tokyo)       Date:  1978-10       Impact factor: 2.649

9.  Cefaclor and cefatrizine, new investigational orally administered cephalosporins. In-vitro collaborative evaluation against clinical bacterial isolates and comparison with related antimicrobics.

Authors:  R N Jones; P C Fuchs; C Thornsberry; A L Barry; T L Gavan; E H Gerlach
Journal:  Am J Clin Pathol       Date:  1979-10       Impact factor: 2.493

10.  In vitro studies with Sch 21420 and Sch 22591: activity in comparison with six other aminoglycosides and synergy with penicillin against enterococci.

Authors:  C C Sanders; W E Sanders; R V Goering
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

View more
  3 in total

1.  In vitro antimicrobial susceptibility to isepamicin of 6,296 Enterobacteriaceae clinical isolates collected at a tertiary care university hospital in Greece.

Authors:  Sofia Maraki; George Samonis; Drosos E Karageorgopoulos; Michael N Mavros; Diamantis Kofteridis; Matthew E Falagas
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

2.  Gentamicin and amikacin disk susceptibility tests with Pseudomonas aeruginosa: definition of minimal inhibitory concentration correlates for susceptible and resistant categories.

Authors:  A L Barry; C Thornsberry; R N Jones
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

3.  In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.

Authors:  Devrim Dundar; Metin Otkun
Journal:  Yonsei Med J       Date:  2009-12-29       Impact factor: 2.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.